Lineage Cell Therapeutics (LCTX) Accumulated Expenses (2011 - 2026)

Lineage Cell Therapeutics' Accumulated Expenses history runs 16 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 40.7% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a 40.7% decrease from a year earlier, with the FY2025 full-year figure at $3.7 million, up 22.11% from the prior year.
• Accumulated Expenses eased to $1.2 million in Q1 2026 per LCTX's latest filing, from $3.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $21.0 million in Q2 2022 and bottomed at $349000.0 in Q3 2023.
• The 5-year median for Accumulated Expenses is $1.9 million (2022), against an average of $2.9 million.
• Across the five-year window, Accumulated Expenses surged 1474.21% in 2022 and plunged 97.23% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $3.8 million in 2022, then declined by 18.52% to $3.1 million in 2023, then fell by 1.83% to $3.1 million in 2024, then advanced by 22.11% to $3.7 million in 2025, then sank by 67.04% to $1.2 million in 2026.
• Per Business Quant, the three latest LCTX Accumulated Expenses figures stand at $1.2 million (Q1 2026), $3.7 million (Q4 2025), and $486000.0 (Q3 2025).